{
    "2019-08-30": [
        [
            {
                "time": "",
                "original_text": "康华生物：主打产品获批涉及行贿 销售费用逐年增高 其他违规处罚",
                "features": {
                    "keywords": [
                        "康华生物",
                        "主打产品",
                        "获批",
                        "行贿",
                        "销售费用",
                        "违规处罚"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物:三代狂犬取得临床总结报告,又一重磅品种即将申报上市",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "三代狂犬",
                        "临床总结报告",
                        "重磅品种",
                        "申报上市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}